NASDAQ
PHAR

Pharming Group NV

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Pharming Group NV Stock Price

Vitals

Today's Low:
$12.8
Today's High:
$12.92
Open Price:
$12.91
52W Low:
$8.65
52W High:
$17.81
Prev. Close:
$12.45
Volume:
1081

Company Statistics

Market Cap.:
$845.04 million
Book Value:
3.04
Revenue TTM:
$206.30 million
Operating Margin TTM:
-13.1%
Gross Profit TTM:
$188.06 million
Profit Margin:
-7.96%
Return on Assets TTM:
-4.1%
Return on Equity TTM:
-8.21%

Company Profile

Pharming Group NV had its IPO on 2020-12-23 under the ticker symbol PHAR.

The company operates in the Healthcare sector and Biotechnology industry. Pharming Group NV has a staff strength of 332 employees.

Stock update

Shares of Pharming Group NV opened at $12.91 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $12.8 - $12.92, and closed at $12.8.

This is a +2.81% increase from the previous day's closing price.

A total volume of 1,081 shares were traded at the close of the day’s session.

In the last one week, shares of Pharming Group NV have increased by +8.21%.

Pharming Group NV's Key Ratios

Pharming Group NV has a market cap of $845.04 million, indicating a price to book ratio of 4.0626 and a price to sales ratio of 3.6344.

In the last 12-months Pharming Group NV’s revenue was $206.30 million with a gross profit of $188.06 million and an EBITDA of $-21412000. The EBITDA ratio measures Pharming Group NV's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Pharming Group NV’s operating margin was -13.1% while its return on assets stood at -4.1% with a return of equity of -8.21%.

In Q2, Pharming Group NV’s quarterly earnings growth was a negative -92.8% while revenue growth was a positive 9.5%.

Pharming Group NV’s PE and PEG Ratio

Forward PE
156.25
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.23 per share while it has a forward price to earnings multiple of 156.25 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pharming Group NV’s profitability.

Pharming Group NV stock is trading at a EV to sales ratio of 3.5392 and a EV to EBITDA ratio of 12.1487. Its price to sales ratio in the trailing 12-months stood at 3.6344.

Pharming Group NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$429.81 million
Total Liabilities
$64.95 million
Operating Cash Flow
$0
Capital Expenditure
$771000
Dividend Payout Ratio
0%

Pharming Group NV ended 2024 with $429.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $429.81 million while shareholder equity stood at $200.37 million.

Pharming Group NV ended 2024 with $0 in deferred long-term liabilities, $64.95 million in other current liabilities, 7540000.00 in common stock, $-265494000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $192.37 million and cash and short-term investments were $192.37 million. The company’s total short-term debt was $5,653,000 while long-term debt stood at $134.18 million.

Pharming Group NV’s total current assets stands at $278.57 million while long-term investments were $9.65 million and short-term investments were $0. Its net receivables were $33.16 million compared to accounts payable of $59.30 million and inventory worth $53.04 million.

In 2024, Pharming Group NV's operating cash flow was $0 while its capital expenditure stood at $771000.

Comparatively, Pharming Group NV paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$12.8
52-Week High
$17.81
52-Week Low
$8.65
Analyst Target Price
$

Pharming Group NV stock is currently trading at $12.8 per share. It touched a 52-week high of $17.81 and a 52-week low of $17.81. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $12.13 and 200-day moving average was $12.11 The short ratio stood at 1.45 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 4.3% are held by institutions.

Frequently Asked Questions About Pharming Group NV

The stock symbol (also called stock or share ticker) of Pharming Group NV is PHAR

The IPO of Pharming Group NV took place on 2020-12-23

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.28
0
+1.75%
$858.75
-23.7
-2.69%
$5.27
0
0%
$65.12
-3.33
-4.86%
James Warren Tea Ltd (JAMESWARREN)
$249.65
0.6
+0.24%
$5.51
-0.07
-1.25%
$21.89
-1.61
-6.85%
$1.69
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Address

Darwinweg 24, Leiden, Netherlands, 2333 CR